A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis

Clinical Gastroenterology and Hepatology

Volumn 2, Issue 12, 2004, Pages 1107-1115

  Sanyal, Arun J ^a,d   Mofrad, Pouneh S ^a   Contos, Melissa J ^b   Sargeant, Carol ^a   Luketic, Velimir A ^a   Sterling, Richard K ^a   Stravitz, R Todd ^a   Shiffman, Mitchell L ^a   Clore, John ^c   Mills, Alan S ^b  

^a Division of Gastroenterology   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^c Virginia Cmw Univ Medical Center   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; PIOGLITAZONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE METABOLISM; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER CLEARANCE; MALE; NONALCOHOLIC FATTY LIVER; RANDOMIZED CONTROLLED TRIAL;

3-HYDROXYBUTYRIC ACID; ALANINE TRANSAMINASE; ANTIOXIDANTS; DRUG THERAPY, COMBINATION; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; FEMALE; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LOGISTIC MODELS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; THIAZOLIDINEDIONES; TREATMENT OUTCOME; VITAMIN E;

EID: 14944359845     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-3565(04)00457-4     Document Type: Article

References (38)

1. J.M. Clark, F.L. Brancati, A.M. Diehl The prevalence and etiology of elevated aminotransferase levels in the United States Am J Gastroenterol 98 2003 960 967
2. A.J. Sanyal AGA technical review on nonalcoholic fatty liver disease Gastroenterology 123 2002 1705 1725
3. S.A. Harrison, S. Torgerson, P.H. Hayashi The natural history of nonalcoholic fatty liver disease a clinical histopathological study Am J Gastroenterol 98 2003 2042 2047
4. C.A. Matteoni, Z.M. Younossi, T. Gramlich, N. Boparai, Y.C. Liu, A.J. McCullough Nonalcoholic fatty liver disease a spectrum of clinical and pathological severity Gastroenterology 116 1999 1413 1419
5. G. Marchesini, M. Brizi, A.M. Morselli-Labate, G. Bianchi, E. Bugianesi, A.J. McCullough, G. Forlani, N. Melchionda Association of nonalcoholic fatty liver disease with insulin resistance Am J Med 107 1999 450 455
6. A.J. Sanyal, C. Campbell-Sargent, F. Mirshahi, W.B. Rizzo, M.J. Contos, R.K. Sterling, V.A. Luketic, M.L. Shiffman, J.N. Clore Nonalcoholic steatohepatitis association of insulin resistance and mitochondrial abnormalities Gastroenterology 120 2001 1183 1192
7. G. Reaven, F. Abbasi, T. McLaughlin Obesity, insulin resistance, and cardiovascular disease Recent Prog Horm Res 59 2004 207 223
8. T. McLaughlin, F. Abbasi, K. Cheal, J. Chu, C. Lamendola, G. Reaven Use of metabolic markers to identify overweight individuals who are insulin resistant Ann Intern Med 139 2003 802 809
9. G.M. Reaven The insulin resistance syndrome Curr Atheroscler Rep 5 2003 364 371
10. F. Diraison, P. Moulin, M. Beylot Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease Diabetes Metab 29 2003 478 485
11. L.P. Turcotte, J.R. Swenberger, T.M. Zavitz, A.J. Yee Increased fatty acid uptake and altered fatty acid metabolism in insulin-resistant muscle of obese Zucker rats Diabetes 50 2001 1389 1396
12. Y. Sumida, T. Nakashima, T. Yoh, M. Furutani, A. Hirohama, Y. Kakisaka, Y. Nakajima, H. Ishikawa, H. Mitsuyoshi, T. Okanoue, K. Kashima, H. Nakamura, J. Yodoi Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease J Hepatol 38 2003 32 38
13. C.P. Oliveira, L.C. Costa Gayotto, C. Tatai, B.I. Della Bina, M. Janiszewski, E.S. Lima, D.S. Abdalla, F.P. Lopasso, F.R. Laurindo, A.A. Laudanna Oxidative stress in the pathogenesis of nonalcoholic fatty liver disease, in rats fed with a choline-deficient diet J Cell Mol Med 6 2002 399 406
14. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults Arch Intern Med 158 1998 1855 1867
15. J.E. Lavine Vitamin E treatment of nonalcoholic steatohepatitis in children a pilot study J Pediatr 136 2000 734 738
16. T. Fujiwara, T. Ohsawa, S. Takahashi, K. Ikeda, A. Okuno, S. Ushiyama, K. Matsuda, H. Horikoshi Troglitazone, a new antidiabetic agent possessing radical scavenging ability, improved decreased skin blood flow in diabetic rats Life Sci 63 1998 2039 2047
17. R.A. DeFronzo, R. Gunnarsson, O. Bjorkman, M. Olsson, J. Wahren Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus J Clin Invest 76 1985 149 155
18. E.M. Brunt, C.G. Janney, A.M. Di Bisceglie, B.A. Neuschwander-Tetri, B.R. Bacon Nonalcoholic steatohepatitis a proposal for grading and staging the histological lesions Am J Gastroenterol 94 1999 2467 2474
19. R.A. DeFronzo, J.D. Tobin, R. Andres Glucose clamp technique a method for quantifying insulin secretion and resistance Am J Physiol 237 1979 E214 E223
20. K.N. Frayn Calculation of substrate oxidation rates in vivo from gaseous exchange J Appl Physiol 55 1983 628 634
21. R. Pasquali, C. Pelusi, S. Genghini, M. Cacciari, A. Gambineri Obesity and reproductive disorders in women Hum Reprod Update 9 2003 359 372
22. J.M. Lord, I.H. Flight, R.J. Norman Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome Cochrane Database Syst Rev 3 2003 CD003053
23. B.A. Neuschwander-Tetri, E.M. Brunt, K.R. Wehmeier, D. Oliver, B.R. Bacon Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone Hepatology 38 2003 1008 1017
24. K. Promrat, G. Lutchman, G.I. Uwaifo, R.J. Freedman, A. Soza, T. Heller, E. Doo, M. Ghany, A. Premkumar, Y. Park, T.J. Liang, J.A. Yanovski, D.E. Kleiner, J.H. Hoofnagle A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis Hepatology 39 2004 188 196
25. H. Ito, A. Nakano, M. Kinoshita, A. Matsumori Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model Lab Invest 83 2003 1715 1721
26. A.H. Berg, T.P. Combs, P.E. Scherer ACRP30/adiponectin an adipokine regulating glucose and lipid metabolism Trends Endocrinol Metab 13 2002 84 89
27. T. Yamauchi, J. Kamon, H. Waki, K. Murakami, K. Motojima, K. Komeda, T. Ide, N. Kubota, Y. Terauchi, K. Tobe, H. Miki, A. Tsuchida, Y. Akanuma, R. Nagai, S. Kimura, T. Kadowaki The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance J Biol Chem 276 2001 41245 41254
28. P. Mofrad, M.J. Contos, M. Haque, C. Sargeant, R.A. Fisher, V.A. Luketic, R.K. Sterling, M.L. Shiffman, R.T. Stravitz, A.J. Sanyal Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values Hepatology 37 2003 1286 1292
29. S.D. Clarke Nonalcoholic steatosis and steatohepatitis. I. Molecular mechanism for polyunsaturated fatty acid regulation of gene transcription Am J Physiol 281 2001 G865 G869
30. F. Assimacopoulos-Jeannet, S. Brichard, F. Rencurel, I. Cusin, B. Jeanrenaud In vivo effects of hyperinsulinemia on lipogenic enzymes and glucose transporter expression in rat liver and adipose tissues Metabolism 44 1995 228 233
31. Y. Matsuzawa, I. Shimomura, T. Nakamura, Y. Keno, K. Tokunaga Pathophysiology and pathogenesis of visceral fat obesity Ann N Y Acad Sci 748 1995 399 406
32. J. Capeau Insulin signaling mechanisms altered in insulin resistance Med Sci (Paris) 19 2003 834 839
33. J.A. Chavez, S.A. Summers Characterizing the effects of saturated fatty acids on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-L1 adipocytes and C2C12 myotubes Arch Biochem Biophys 419 2003 101 109
34. G. Marchesini, M. Brizi, G. Bianchi, S. Tomassetti, E. Bugianesi, M. Lenzi, A.J. McCullough, S. Natale, G. Forlani, N. Melchionda Nonalcoholic fatty liver disease a feature of the metabolic syndrome Diabetes 50 2001 1844 1850
35. D. Pessayre, A. Berson, B. Fromenty, A. Mansouri Mitochondria in steatohepatitis Semin Liver Dis 21 2001 57 69
36. D. Pessayre, A. Mansouri, B. Fromenty Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis Am J Physiol 282 2002 G193 G199
37. P. Roychoudhury, K. Schwartz Antioxidant vitamins do not prevent cardiovascular disease J Fam Pract 52 2003 751 752
38. R. Clarke, J. Armitage Antioxidant vitamins and risk of cardiovascular disease. Review of large-scale randomised trials Cardiovasc Drugs Ther 16 2002 411 415